UCSF UC San Francisco Previously Published Works

Title

General payments from Biogen to U.S. physicians between 2015 and 2020

Permalink

https://escholarship.org/uc/item/8nw089d4

Journal

Journal of the American Geriatrics Society, 70(10)

ISSN 0002-8614

Authors

Jenei, Kristina Lythgoe, Mark P Prasad, Vinay

Publication Date

2022-10-01

DOI

10.1111/jgs.17911

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at https://creativecommons.org/licenses/by/4.0/

Peer reviewed

Check for updates

DOI: 10.1111/jgs.17911

General payments from Biogen to U.S. physicians between 2015 and 2020

INTRODUCTION

The approval of aducanumab (Aduhelm) for Alzheimer's disease is one of the most consequential and criticized decisions the U.S. Food and Drug Administration (FDA) has made in recent years.¹ Indeed, the accelerated approval ignited a federal investigation due to a confluence of factors, most notably an opaque relationship between the company and the U.S. FDA that facilitated the approval of a drug with poor clinical evidence.²

One unknown element of the aducanumab controversy is the financial conflict of interests between the manufacturer and U.S. physicians. It is well-established that pharmaceutical companies provide financial incentives to medical professionals.^{3–6} The Open Payments (OP) database was established to track industry payments as part of the Physician Payment Sunshine Act. Since its inception, numerous studies have explored payments across medical specialties, including linking these data with Medicare to demonstrate how even small sums can influence prescribing.³ Therefore, we characterized payments from Biogen to U.S. physicians to understand where financial conflict of interests might exist and provide a baseline for future evaluations.

METHODS

We conducted a systematic search of OP dataset⁷ between 2015 and 2020 to identify all generic payments made to physicians from Biogen (excluding research contributions). General payments include consulting fees, education costs, meal and travel expenses, and grants. OP database includes an "other" category for non-consulting services such as speaking fees.⁷ Due to the nature of search through the company profile, the "other" category could not be further aggregated into discrete categories. We quantified payments from Biogen to physicians by speciality, drug, nature, and "significant" payments over \$10,000 dollars per year. Since aducanumab is indicated for Alzheimer's disease, we performed an analysis of specialities likely to be involved in prescribing, such as geriatric psychiatry and geriatric medicine subspecialists. OP dataset categories physicians by primary residency therefore subspecialists coded "geriatrics" were from family medicine, internal medicine, and neurology. Finally, we investigated payments associated with drugs listed on Biogen's product portfolio. One limitation of OP dataset is that there are numerous payments not assigned an identifier. These funds yield a "blank" and were not included in this analysis. Descriptive data analyses were performed using Excel Software v16.50.

TABLE 1Summary characteristics of Biogen payments tophysicians between 2015 and 2020

physicians between 2015 and 2020		
	Variable	Total number (%)
	Physicians	
	# Physicians	33,505 (100)
	# physicians receiving over \$10,000	1864 (6)
	Payments	
	# of payments	273,727 (100)
	Total value (\$ USD)	82,178,093 (100)
	Median payment value (IQR)	97 (79–105)
	Top payments by specialty (% total)	
	Neurology	67,202,433 (82)
	Internal medicine	6,688,899 (8)
	Pediatrics	2,384,452 (3)
	Surgery (all)	1,100,698 (1)
	Family medicine	757,469 (1)
	Radiology	831,679 (1)
	Other	3,212,463 (4)
	Subspecialists	
	Geriatric psychiatry	\$23,000 (0)
	Geriatric family practice	\$8400 (0)
	Geriatric internal medicine	\$236,600 (0)
	Therapeutics ^a	
	# of payments	247,096 (100)
	Total value (\$USD)	54,513,855 (100)
Drug (trade name)		
	Aducanumab (Aduhelm)	NR
	Nusinersen (Spinraza)	6,525,110 (13)
	Peginterferon beta-1a (Plegridy)	6,228,084 (12)
	Diroximel fumarate (Vumerity)	1,816,426 (4)
	Dimethyl fumarate (Tecfidera)	18,560,112 (36)
	Dalfampridine (Fampyra)	8103 (0)
	Natalizumab (Tysabri)	13,589,989 (26)
	Interferon beta-1a (Avonex)	721,524 (1)
	Other	4,132,411 (8)

Abbreviation: NR, not reported.

^aList based on U.S. marketed therapeutics per Biogen product profile.

RESULTS

From 2015 to 2020, Biogen made 273,727 non-research payments to 33,505 physicians totaling \$82,179,093 (Table 1). The median annual payment was \$97 (IQR: \$79–\$105). Annual payments decreased across all specialities except for neurologists who experienced an increase within the study period (except 2020) (Figure 1).


The decrease of total payments in 2020 might be COVIDrelated as the total proportion of payments shifted from travel (which decreased 6%) to non-research grants (increased by 13%). Approximately 44% of payments were related to activities coded under the "other" category (such as speaking fees), followed by consulting (36%), travel (7%), meals (6%), and grants (6%).


Neurologists were the highest paid physician specialists receiving \$67,202,433 (82%) of total payments, followed by internal medicine (8%), pediatrics (3%), family medicine, surgery, and radiology (all 1%) (Figure 1). Biogen gave \$268,000 to geriatric subspecialists consisting of consulting fees (92%), travel (6%), and meals (2%). Of these, geriatric psychiatry (neurology) received \$23,000. Geriatric medicine subspecialists from family medicine received \$8400 and internal medicine \$236,600. There were 1864 (6%) physicians who received over \$10,000 per year. Of these, 1588 (85%) were neurologists. Over half of payments in OP dataset (66%) were associated with a drug. Of those reported, dimethyl fumarate (36%) was the top drug in total amount, followed by natalizumab (26%), nusinersen (13%), and peginterferon beta-1a (12%) (Table 1).

DISCUSSION

Our analysis demonstrates that financial payments from Biogen are widespread across medical specialities. However, 82% of funds were given to neurologists. In fact, approximately 40% of practicing neurologists in the United States have received general payments from Biogen. One possible explanation for this overrepresentation might be the nature of Biogen's Product Portfolio which is dominated by drugs for neurological ailments. Neurologists also received 85% of payments over \$10,000, which might suggest an industry strategy to concentrate payments to one group.

Financial payments are a widespread marketing strategy used by pharmaceutical companies³ and is not limited to physicians but stakeholders across medicine such as national academies,⁸ journal editors,⁹ nurse practitioners, and physician assistants.¹⁰ Further, more than two thirds of U.S. Congress received payments from top pharmaceutical companies in 2020, such as Pfizer, Amgen, Biogen, among others.¹¹ This is concerning as numerous studies have found financial payments influence behavior toward increased prescribing, more costly prescriptions, and a higher use of brand name medicines.^{3,10} In the case of aducanumab, incentives for increased prescribing would exacerbate the negative forecasted impacts on health system and patients across the nation.





AUTHOR CONTRIBUTIONS

All authors were involved in the preparation of the manuscript and data interpretation. Drs. Lythgoe and Prasad were involved with conceptualization, drafting, and editing of the manuscript, along with supervision. Ms. Jenei had primary access to the data and takes responsibility for the analysis.

FUNDING INFORMATION

Arnold Ventures

CONFLICT OF INTEREST

Dr Prasad reports (Research funding) Arnold Ventures (Royalties) Johns Hopkins Press, MedPage, YouTube, Substack (Consulting) Optum Health. (Other) Plenary Session podcast has Patreon (https://www.patreon.com/ plenarysession) backers. Dr. Lythgoe has received advisory fees from Clovis Oncology outside the submitted work. Ms. Jenei reports no conflicts.

SPONSOR'S ROLE

The sponsor did not have a role in the manuscript.

Kristina Jenei BSN, MSc¹ D Mark P. Lythgoe MBBS² Vinay Prasad MD, MPH³

¹School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, V6T1Z3, Canada ²Department of Surgery and Cancer, Imperial College London, London, UK ³Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States

Correspondence

Kristina Jenei, School of Population and Public Health, University of British Columbia, 2206 East Mall Vancouver, British Columbia, V6T1Z3, Canada. Email: kjenei@mail.ubc.ca

ORCID

Kristina Jenei D https://orcid.org/0000-0002-3635-5212

REFERENCES

- Steinbrook R. The accelerated approval of aducanumab for treatment of patients with Alzheimer disease. *JAMA Intern Med.* 2021; 181:1281. doi:10.1001/JAMAINTERNMED.2021.4622
- Walsh S, Merrick R, Milne R, Brayne C. Aducanumab for Alzheimer's disease? *BMJ*. 2021;374:n1682. doi:10.1136/BMJ.N1682
- Mitchell AP, Trivedi NU, Gennarelli RL, et al. Are financial payments from the pharmaceutical industry associated with physician prescribing? A systematic review. *Ann Intern Med.* 2021;174(3):353-361. doi:10.7326/M20-5665
- Hayes MJ, Prasad V. Financial conflicts of interest at FDA drug advisory committee meetings. *Hastings Cent Rep.* 2018;48(2): 10-13. doi:10.1002/HAST.833
- Kaestner V, Brown A, Tao D, Prasad V. Conflicts of interest in twitter. *Lancet Haematol.* 2017;4(9):e408-e409. doi:10.1016/ S2352-3026(17)30109-6

- JAGS_JAGS_
- Gill J, Haslam A, Crain T, Herrera-Perez D, Prasad V. Comparison of industry payments in 2017 with annual salary in a cohort of academic oncologists. *JAMA Intern Med.* 2020;180(5): 797-799. doi:10.1001/JAMAINTERNMED.2020.0090
- 7. Open Payments Natures of Payment | CMS. Accessed July 8, 2021. https://www.cms.gov/OpenPayments/Natures-of-Payment
- 8. Report of the Treasurer for the Year Ended December 31, 2020. *Rep Treas Year End December 31, 2020*; June 2021. doi:10.17226/26227
- 9. Liu JJ, Bell CM, Matelski JJ, Detsky AS, Cram P. Payments by US pharmaceutical and medical device manufacturers to US

medical journal editors: retrospective observational study. *BMJ*. 2017;359:j4619. doi:10.1136/BMJ.J4619

- Wood SF, Podrasky J, McMonagle MA, et al. Influence of pharmaceutical marketing on Medicare prescriptions in the District of Columbia. *PLoS One.* 2017;12(10):e0186060. doi:10.1371/ JOURNAL.PONE.0186060
- 11. Two-Thirds of Congress Cashed a Pharma Campaign Check in 2020. Accessed April 1, 2022. https://www.statnews.com/feature/ prescription-politics/federal-full-data-set/